The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors
Official Title: A Phase Ib Study of Tolerance and Safety of a Recombinant Anti-PD-1 Monoclonal Antibody HX008 in Patients With Advanced Solid Tumors
Study ID: NCT04825392
Brief Summary: HX008 is a humanized monoclonal antibody targeting PD-1 on the T cell surface, restores T cell activity, thus enhancing immune response, and has the potential to treat various types of tumors. In this study, the tolerance and safety of HX008 in patients with advanced solid tumors will be evaluated.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hunan Cancer Hospital, Changsha, , China
Hunan Cancer Hospital, Changsha, , China
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, , China